OSL announces $8.7m capital raise to drive commercialisation
Filed with ASX · · 7 pages · English
Summary by 6ix AI
OncoSil Medical Ltd has announced a capital raise to support its commercialization efforts, securing commitments for a significant amount from both existing and new shareholders, including institutional investors. The funds will primarily be used to advance the commercialization of the OncoSil medical device for treating pancreatic cancer across Europe and other regions. The company expects to achieve cash flow breakeven by the second half of the upcoming year, following the completion of key clinical trials. This announcement outlines the details of the capital raise, including the structure of the placement and share purchase plan.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from OncoSil Medical
- Consolidation/Split - OSL
- 120 German Hospitals entitled to negotiate fee for OncoSil
- OncoSil Medical Receives MDR Approval
- OncoSil receives $1.05m R&D tax incentive
- Oncosil completes $1 million Share Purchase Plan (SPP)
Later from OncoSil Medical
- Completion of Recruitment in PANCOSIL Study
- Completion of Recruitment in TRIPP-FFX Clinical Trial
- Appendix 4E and Annual Report
- Positive Preliminary Results from PANCOSIL Phase 1-2 Study
- Response to ASX Aware Letter
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical